Skip to content

Effect of Hemodialysis on Upper Airways Collapsibility in Patients With Chronic Kidney Disease

Effect of Hemodialysis on Upper Airways Collapsibility in Patients With Chronic Kidney Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02390193
Enrollment
52
Registered
2015-03-17
Start date
2015-01-02
Completion date
2020-12-03
Last updated
2018-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Insufficiency, Chronic

Keywords

Chronic kidney disease, Dialysis, Sleep, Pulmonary function, Polysomnography, Upper airway

Brief summary

Introduction: Currently, chronic kidney disease (CKD) is one of the most serious public health problems, becoming a global epidemic. It is also known that the amount of displacement of overnight rostral fluid, from the lower limbs, is related to increased neck circumference and severity of obstructive sleep apnea (OSA) in patients with end-stage renal disease. Method / Design: A clinical trial study aiming to assess the degree of collapsibility of the upper airway in patients with CKD undergoing hemodialysis has been proposed. The test of the negative expiratory pressure and nocturnal polysomnography will be performed before and after the hemodialysis session. Discussion: The incidence of CKD has increased, due to the increased number of cases of diabetes mellitus and hypertension. Our hypothesis is that the weight gain due to volume overload, observed in the interdialytic period, will exert a negative influence on the degree of collapsibility of the upper airways predispose to OSA in CKD patients.

Interventions

PROCEDUREHemodialysis

Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C. The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers. The patients who required a change in medication for medical reasons were subsequently excluded from the study.

Sponsors

Irmandade da Santa Casa de Misericordia de Sao Paulo
CollaboratorOTHER
Centro Universitário de Anapolis
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* male or female patients aged 18 to 80 years; * chronic kidney failure; * candidate for kidney transplant with indication for dialysis; * cognitive level sufficient for understanding the procedures and following the instructions; * absence of dementia or treatment-refractory psychiatric diseases leading to an inability to provide informed consent. * and agreement to participate by signing a statement of informed consent.

Exclusion criteria

* craniofacial abnormalities; * undergoing active treatment of sleep apnea; * active malignancy; * active alcohol and/or drug abuse;

Design outcomes

Primary

MeasureTime frameDescription
Collapsibility of the upper airway.06 monthsDegree of upper airway collapsibility through the negative expiratory pressure test in patients with chronic kidney disease on hemodialysis.

Secondary

MeasureTime frameDescription
Prevalence and severity of sleep disorders06 monthsTo assess the effects of dialysis on sleep parameters and determine the prevalence and severity of sleep disorders.
Change in pulmonary function.06 monthsLung function tests will be performed during the day, with the patient seated in a comfortable position. For such, the KoKo PFT Spirometer System version 4.11 (nSpire Health, Inc, Louisville, CO, USA) will be used in accordance with the guidelines for the execution of lung function tests established by the Brazilian Society of Pneumology and European Respiratory Society.

Countries

Brazil

Contacts

Primary ContactLuis VF Oliveira, PhD
oliveira.lvf@pq.cnpq.br+55 62 999052309

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026